Boehringer Ingelheim Initiates Phase IIa Study Of Compound Acquired From Pharmaxis In Debilitating Liver Disease NASH – biolegacy

Boehringer Ingelheim Initiates Phase IIa Study Of Compound Acquired From Pharmaxis In Debilitating Liver Disease NASH

Post author:Sam
Post published:August 24, 2017
Post category:BioPharma

Life Sciences Jobs …
Source: BioSpace